Evolent Health, Inc. (NYSE:EVH) Shares Acquired by Barclays PLC

Barclays PLC boosted its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 181.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 273,776 shares of the technology company's stock after purchasing an additional 176,445 shares during the quarter. Barclays PLC owned approximately 0.23% of Evolent Health worth $7,742,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of Evolent Health by 12.8% during the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company's stock worth $356,200,000 after buying an additional 1,426,747 shares during the period. Point72 Asset Management L.P. raised its position in Evolent Health by 1,948.5% during the third quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company's stock worth $42,289,000 after acquiring an additional 1,422,385 shares during the period. William Blair Investment Management LLC raised its position in Evolent Health by 35.2% during the second quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company's stock worth $96,098,000 after acquiring an additional 1,308,376 shares during the period. First Light Asset Management LLC lifted its holdings in Evolent Health by 401.5% during the second quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company's stock valued at $27,634,000 after purchasing an additional 1,157,124 shares in the last quarter. Finally, Bellevue Group AG grew its position in shares of Evolent Health by 59.9% in the third quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company's stock valued at $75,509,000 after purchasing an additional 1,000,215 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EVH. Truist Financial restated a "buy" rating and set a $33.00 price target on shares of Evolent Health in a research report on Tuesday, August 27th. Barclays reduced their target price on Evolent Health from $39.00 to $19.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Citigroup lowered their price target on Evolent Health from $33.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reduced their price objective on Evolent Health from $45.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, November 22nd. Finally, Oppenheimer decreased their price objective on Evolent Health from $34.00 to $28.00 and set an "outperform" rating on the stock in a report on Monday, November 18th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $26.18.

Evolent Health Trading Up 4.4 %

Evolent Health stock traded up $0.47 during midday trading on Thursday, hitting $11.18. 3,385,837 shares of the stock were exchanged, compared to its average volume of 1,863,080. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock's 50-day simple moving average is $16.97 and its 200 day simple moving average is $22.23. Evolent Health, Inc. has a fifty-two week low of $10.53 and a fifty-two week high of $35.00. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -12.29 and a beta of 1.45.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.